For investors
A platform, not a clinic.
Recurring, contracted renal-care economics across a nine-company ecosystem — built to list.
Recurring, contracted renal-care economics across a nine-company ecosystem — built to list.
Nine companies covering every layer a dialysis center needs — each earning on its own, inside the network and out.
Dialysis is three sessions a week, for life, government-funded per session. Revenue recurs by clinical necessity.
Renovia Finance pays centers for PhilHealth claims today — the wedge that compounds the network with every receivable factored.
Chairs, treatment packs, refurbishment — manufacturing layers that convert outsourced cost into owned margin.
The provinces are underserved while PhilHealth pays the same ₱6,350 everywhere. Thin competition, equal economics.
Intent to list on the PSE within ~3 years, with staged financing waypoints along the way. Directional, stated plainly.
Specific multiples, valuations, MOIC / IRR, and the cap table live behind the data room.
PhilHealth claims are growing 15.5% a year against a fixed national chair count. The nine companies exist and operate. What scale needs now is build capital — and early conviction is priced accordingly.
The institutional memo, the operating model, and the investor deck are shared after a short qualification call. Requests route directly to Edward Reyes, Investor Relations — no instant downloads, no mass mailings.
Edward Reyes will reach out to qualify access — usually within two business days.